Superworth

Oramed Pharmaceuticals EV/EBIT ORMP

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2014.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
157×
Nov 2016
Peer median
3.5×

Oramed Pharmaceuticals has no meaningful EV/EBIT today: it made an operating loss of $14.5M over the last twelve months.

It was last meaningful in Nov 2016, at 157×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2016157×144×201×
2015123×39.0×130×
201434.5×34.5×53.9×

Against its peers

Companies in Drug Manufacturers - General nearest Oramed Pharmaceuticals' size, closest first, today.

CompanyEV/EBIT
ORMPOramed Pharmaceuticalsn/m
NATRNatures Sunshine Products5.2×
LFVNLifevantage9.6×
SPROSpero Therapeutics2.1×
ARVNArvinasn/m
PBYIPuma Biotechnology15.6×
IRWDIronwood Pharmaceuticals3.5×
ZVRAZevra Therapeutics2.9×
CRMDCorMedix2.3×
ATNMActinium Pharmaceuticals1.2×
COLLCollegium Pharmaceutical9.4×
Peer median3.5×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Oramed Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.